> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Teva Recalls Combo Products for High Blood Pressure
- URL: https://www.fdaweb.com/teva-recalls-combo-products-for-high-blood-pressure/
- Published: 2018-11-28T12:00:00.000Z
- Updated: 2026-09-15T00:47:11.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5142913

Teva Pharmaceuticals has recalled all lots of amlodipine/valsartan combination tablets and amlodipine/valsartan/hydrochlorothiazide combination tablets due to an impurity detected above specification limits in an active pharmaceutical ingredient manufactured by Mylan India. The impurity found in Mylan’s valsartan API is identified as N-nitroso-diethylamine (NDEA), which has been classified as a probable human carcinogen, according to a [recall notice](https://www.fda.gov/Safety/Recalls/ucm626802.htm?ref=fdaweb.com). The combination tablets are used for treating high blood pressure. To date, Teva says it has not received any reports of adverse events signaling a potential link or exposure to valsartan.